2-氨基-n-苯基乙烷磺酰胺 | 25840-61-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-n-苯基乙烷磺酰胺
• 英文名称: 2-aminoethane-N-phenylsulfonamide
• 英文别名: 2-amino-ethanesulfonic acid anilide；2-Amino-aethansulfonsaeure-anilid；Taurin-anilid；2-amino-ethanesulfonic acid phenylamide；2-amino-N-phenylethanesulfonamide
• CAS: 25840-61-3
• 化学式: C₈H₁₂N₂O₂S
• mdl: MFCD09730216
• 分子量: 200.261
• InChiKey: AMJWROHRKLMFBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氨基-n-苯基乙烷磺酰胺 、 D-(-)-泛酰内酯 生成 (R)-2.4-dihydroxy-3.3-dimethyl-N-(2-phenylsulfamoyl-ethyl)-butyramide
  参考文献：
  名称：

  化疗研究；泛酰牛磺酸的酰胺。

  摘要：

  DOI：

  10.1021/ja01198a047
• 作为产物：
  描述：

  N-phenyl-2-phthalimidoethanesulfonamide 在 水 、 肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以40%的产率得到2-氨基-n-苯基乙烷磺酰胺
  参考文献：
  名称：

  Synthesis and QSAR of Quinazoline Sulfonamides As Highly Potent Human Histamine H₄ Receptor Inverse Agonists

  摘要：

  Hit optimization of the class of quinazoline containing histamine H-4 receptor (H4R) ligands resulted in a sulfonamide substituted analogue with high affinity for the H4R. This moiety leads to improved physicochemical properties and is believed to probe a distinct H4R binding pocket that was previously identified using pharmacophore modeling. By introducing a variety of sulfonamide substituents, the H4R affinity was optimized. The interaction of the new ligands, in combination with a set of previously published quinazoline compounds, was described by a QSAR equation. Pharmacological studies revealed that the sulfonamide analogues have excellent H4R affinity and behave as inverse agonists at the human H4R. In vivo evaluation of the potent 2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-N-phenylethanesulfonamide (54) (pK(i) = 8.31 +/- 0.10) revealed it to have anti-inflammatory activity in an animal model of acute inflammation.

  DOI：

  10.1021/jm901379s

文献信息

• [EN] DIPEPTIDYL PEPTIDASE INHIBITORS<br/>[FR] INHIBITEURS DE DIPEPTIDYL PEPTIDASE
  申请人：SYRRX INC

  公开号：WO2004103993A1

  公开（公告）日：2004-12-02

  Pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound with the formula: (I) where the labeled substituents are as described herein.

  提供了用于与DPP-IV和其他S9蛋白酶一起使用的药物、试剂盒和方法，其中包括具有以下结构的化合物：(I)，其中标记的取代基如本文所述。
• Quinazolines and related heterocyclic compounds and their therapeutic use
  申请人：Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg

  公开号：EP2077263A1

  公开（公告）日：2009-07-08

  A compound of the formula wherein X is CR1 or N; Y is CR3 or N; R1, R3, R4, R5 and R6 are independently H, F, Cl, Br, I, or a hydrocarbon group which optionally contains one or more heteroatoms; R7 is a heterocyclic group including one or more N atoms; R' is Rx or NRyRz wherein Rx, Ry and Rz are each H or the same or different groups, including cyclic groups formed by Ry and Rz with the N atom, of up to 20 C atoms and optionally including up to 3 further heteroatoms selected from N, O and S; or a pharmaceutically acceptable salt, ester or solvate thereof, has therapeutic utility.

  该化合物的公式为X是CR1或N；Y是CR3或N；R1、R3、R4、R5和R6分别独立地为H、F、Cl、Br、I或一个可能含有一个或多个杂原子的碳氢基团；R7是一个包括一个或多个N原子的杂环基团；R'是Rx或NRyRz，其中Rx、Ry和Rz分别为H或相同或不同的基团，包括由Ry和Rz与N原子形成的环基团，最多包含20个碳原子，且可选地包含最多3个进一步从N、O和S中选择的杂原子；或其药用盐、酯或溶剂化合物具有治疗用途。
• [EN] C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE<br/>[FR] DÉRIVÉ DE MACROLIDE SUBSTITUÉ EN POSITION C-4"
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2012115256A1

  公开（公告）日：2012-08-30

  A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).

  一种由化学式（I）表示的大环内酯化合物，对红霉素耐药细菌有效（例如，耐药的肺炎球菌、链球菌和支原体）。
• Isoxazole Derivatives and Use Thereof
  申请人：Cho Jeong Woo

  公开号：US20090131336A1

  公开（公告）日：2009-05-21

  Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.

  本文披露了异噁唑衍生物及其用途。作为Wnt的激动剂，异噁唑衍生物激活Wnt/β-连环蛋白信号传导，因此可用于治疗和预防与信号传导相关的疾病。此外，还披露了异噁唑衍生物的药用盐。
• Dipeptidyl peptidase inhibitors
  申请人：Syrrx, Inc.

  公开号：US20040254226A1

  公开（公告）日：2004-12-16

  Pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound with the formula: 1 where the labeled substituents are as described herein.

  提供了用于与DPP-IV和其他S9蛋白酶一起使用的制药品、试剂盒和方法，其中包括具有以下公式的化合物：1，其中标记的取代基如此处所述。